Sandoz is a world leader in generic pharmaceuticals, finding innovative ways to making medicines affordable and accessible to more than 90 percent of the world’s population.Learn more about our company
Visions and Values
Increasing access to medicines against chronic diseases
Sandoz receives FDA approval for Glatopa™ as the first generic competitor to MS therapy Copaxone® 20mg
This approval reinforces Sandoz leadership in complex, differentiated generic products.
November 20, 2015
Sandoz, a Novartis company, today announces the launch of AirFluSal® Forspiro®, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in the United Kingdom....
Our people are our greatest resource. We are always looking for new colleagues to share in our commitment to make the world a healthier place.Learn more about careers at Sandoz
Watch our videos to discover more about the world of Sandoz and the generics market.Visit our video gallery to watch the latest episode